Bio-Rad Laboratories
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Bio-Rad Laboratories generated cash of $374,943,000, which is more than the previous year. Cash used in financing activities reached the amount of -$425,647,000 last year. Net change in cash is therefore -$30,175,000.
Cash Flow
| 2014 | 273.31M | -190.51M | 11.68M |
|---|---|---|---|
| 2015 | 186.21M | -166.86M | 8.58M |
| 2016 | 216.43M | -213.88M | 9.02M |
| 2017 | 103.88M | -175.57M | 341K |
| 2018 | 285.49M | -186.97M | -48.68M |
| 2019 | 457.89M | -208.88M | -22.75M |
| 2020 | 575.32M | -60.25M | -523.04M |
| 2021 | 656.52M | -784.43M | -55.42M |
| 2022 | 194.44M | -1.20B | 973.57M |
| 2023 | 374.94M | 20.20M | -425.64M |
BIO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 434.54M | 471.13M | 667.11M | 662.65M | 434.16M | 384.98M | 456.26M | 457.54M | 413.25M | 331.55M |
Operating activities | ||||||||||
Net income | -637.32M | -3.62B | 4.24B | 3.80B | 1.75B | 360.99M | 114.74M | 28.12M | 113.09M | 88.84M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 137.29M | 133.80M | 138.12M | 134.23M | 138.08M | 148.68M | 142.89M | 131.84M | 149.88M |
Stock-based compensation expense | 61.3M | 60.9M | 51.2M | 41.6M | 35.6M | 27.8M | 23.4M | 19.7M | 17M | 14.9M |
| Deferred income tax benefit | 61.3M | 60.9M | 51.2M | 41.6M | 35.6M | 27.8M | 23.4M | 19.7M | 17M | 14.9M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 11.4M | -87.4M | -20.4M | -15M | 1.6M | 59.7M | -64.1M | 12.5M | -39M | 11.1M |
Inventories | 0 | -158.8M | 46.1M | -52.1M | 24.2M | -12.9M | -47.7M | -57.1M | -54.2M | 5.8M |
Accounts payable | -51.8M | -94.2M | 69.9M | 124.7M | 10.6M | -45.6M | 7.8M | 30.1M | 28.6M | -9.9M |
Cash generated by operating activities | 374.94M | 194.44M | 656.52M | 575.32M | 457.89M | 285.49M | 103.88M | 216.43M | 186.21M | 273.31M |
Investing activities | ||||||||||
Purchases Of Investments | -689.04M | -2.06B | -1.30B | -345.11M | -450.83M | -370.75M | -282.65M | -278.07M | -294.49M | -205.74M |
Investments In Property Plant And Equipment | -156.68M | -114.15M | -120.80M | -98.92M | -98.53M | -129.82M | -115.12M | -141.57M | -113.37M | -136.47M |
Acquisitions Net | 0 | -100.74M | -125.51M | -96.65M | -79.38M | 6.96M | -76.64M | -14.16M | -4.35M | -44.62M |
Cash generated by investing activities | 20.20M | -1.20B | -784.43M | -60.25M | -208.88M | -186.97M | -175.57M | -213.88M | -166.86M | -190.51M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 35.28B | 20.19M | 0 | 0 | 0 | 11.28M | 8.23M | 15.05M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -428.72M | -215.67M | -49.99M | -112.93M | -28M | -57.77M | -2.92M | 0 | 0 | 0 |
Repayments of term debt | -467K | 1.18B | -3.02M | -426.93M | -643K | -2.96M | -352K | -303K | -282K | -253K |
Cash used in financing activities | -425.64M | 973.57M | -55.42M | -523.04M | -22.75M | -48.68M | 341K | 9.02M | 8.58M | 11.68M |
Net Change In Cash | -30.17M | -36.58M | -195.98M | 4.46M | 228.48M | 49.18M | -72.44M | -1.28M | 44.29M | 81.7M |
Cash at end of period | 404.36M | 434.54M | 471.13M | 667.11M | 662.65M | 434.16M | 383.82M | 456.26M | 457.54M | 413.25M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |